By Arasu Kannagi Basil Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of ...

Generate:Biomedicines has hit the public markets as the world begins to question the usefulness of AI technology. CEO Mike Nally says biology is the key to unlocking the technology’s full potential.

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. | Generate:Biomedicines is the latest biotech to benefit from a ...

The Somerville-based company, which uses its proprietary AI system in drug engineering and development, is seeking to go public amid a jump in biotech and pharma IPO volume.

The AI drug discovery specialist is the fifth biotechnology company to go public in February and priced the sector’s largest ...

Flagship Pioneering-founded Generate Biomedicines is tacking on a gigantic $273 million in series C funds, though the haul didn't reach the heights of the biotech’s previous $370 million raise back in ...

Flagship Pioneering-backed artificial intelligence start-up Generate:Biomedicines has attracted another big pharma partnership, this time with Novartis. The wide-ranging deal, worth up to $1 billion, ...

Generate:Biomedicines plans to raise around $400 million in its initial public offering — a sum that hasn’t been seen for ...

By Pragyan Kalita and Pritam Biswas Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 ...

As part of its mission to open new sources of capital for the clean energy transition, Generate has deepened partnerships with insurance companies, pension plans and existing shareholders seeking ...